Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures
DH Lee - Pharmacology & therapeutics, 2017 - Elsevier
The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung …
YT Lin, JS Chen, WY Liao, CC Ho… - … Journal of Cancer, 2019 - Wiley Online Library
Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
[HTML][HTML] Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non …
R Saito, S Sugawara, R Ko, K Azuma, R Morita… - European Journal of …, 2023 - Elsevier
Background This multicenter phase 2 trial evaluated the safety and efficacy of osimertinib
and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR …
and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR …
[HTML][HTML] Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients …
Background Despite the potent efficacy of epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitors (TKIs) in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) …
kinase inhibitors (TKIs) in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) …
[HTML][HTML] Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
NN Lou, XC Zhang, HJ Chen, Q Zhou, LX Yan, Z Xie… - Oncotarget, 2016 - ncbi.nlm.nih.gov
The co-occurrence of epidermal growth factor receptor (EGFR) mutations and anaplastic
lymphoma kinase (ALK) rearrangements constitutes a rare molecular subtype of non-small …
lymphoma kinase (ALK) rearrangements constitutes a rare molecular subtype of non-small …
[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase …
S Miura, H Tanaka, T Misumi, H Yoshioka… - Annals of …, 2023 - annalsofoncology.org
Background EGFR mutations are diverse and include major uncommon and compound
mutations. There is no conclusion on whether EGFR-TKI is the optimal treatment for these …
mutations. There is no conclusion on whether EGFR-TKI is the optimal treatment for these …
Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
Z Lian, W Du, Y Zhang, Y Fu, T Liu, A Wang… - Thoracic …, 2020 - Wiley Online Library
Background Although many studies have defined mechanisms of resistance to EGFR‐TKIs,
acquired resistance remains the major limitation of monotherapy with EGFR‐TKIs. Methods …
acquired resistance remains the major limitation of monotherapy with EGFR‐TKIs. Methods …
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and …
Y Zhao, S Wang, B Zhang, R Qiao, J Xu, L Zhang… - Targeted Oncology, 2019 - Springer
Background Patients harboring concomitant epidermal growth factor receptor (EGFR)
mutations and anaplastic lymphoma kinase (ALK) arrangements constitute a small subgroup …
mutations and anaplastic lymphoma kinase (ALK) arrangements constitute a small subgroup …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …